Nu Skin Enterprises Announces Resignation of CFO; Reiterates First Quarter and 2023 Outlook
Nu Skin Enterprises (NYSE: NUS) announced the resignation of CFO Mark Lawrence, effective March 31, 2023, to pursue other opportunities. Lawrence will continue as a senior advisor until April 2023 to ensure a smooth transition. The board has appointed James D. Thomas, previously the chief accounting officer, as interim CFO while searching for a permanent replacement. The company reaffirmed its first-quarter and annual guidance for 2023, initially provided on February 15, 2023. Nu Skin will release its Q1 results on May 3, 2023, followed by a conference call with investors.
- James D. Thomas has extensive experience within the company, potentially ensuring continuity.
- The company reiterated its guidance for 2023, indicating confidence in meeting financial expectations.
- The resignation of a key executive may create uncertainty in financial management.
- Transitioning to an interim CFO could disrupt ongoing financial strategies and operations.
Company to release Q1 results
"On behalf of our board, management and the entire
The company will announce first-quarter results after the market closes on
About
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's revenue and earnings guidance for the first quarter and the full year, as well as its future performance.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
- issues that could arise during the company's closing and review/audit procedures, such as the need to make an adjustment to the projected numbers;
- risk that epidemics, including COVID-19 and related disruptions, and other crises could negatively impact our business;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of the company's markets, including
the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events; - any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
- uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
- risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future financial performance of the businesses the company has acquired;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally;
- the company's future tax-planning initiatives; any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets outside of
the United States ; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and - continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/nu-skin-enterprises-announces-resignation-of-cfo-reiterates-first-quarter-and-2023-outlook-301786465.html
SOURCE
FAQ
What impact will Mark Lawrence's resignation have on Nu Skin's financial strategies?
Who is the interim CFO at Nu Skin after Mark Lawrence's resignation?
When will Nu Skin announce its first quarter results for 2023?